Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 09.06.2025 1 Am J Surg Pathol 4 BJU Int 1 BMC Urol 1 Br J Radiol 3 Eur Urol 2 Int J Urol 1 J Clin Lab Anal 1 J Clin Oncol 1 J Natl Med Assoc 4 J Nucl Med 2 J Urol 2 Magn Reson Imaging 1 PLoS Biol 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Radiol Imaging Cancer 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. SHAH RB, Paner GP, Cheng L, De Marzo AM, et al
   Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer.
   Am J Surg Pathol. 2025 May 30. doi: 10.1097/PAS.0000000000002425.
   PubMed         Abstract available
   
   

   
   BJU Int

2. 
   Prostate cancer: detection, treatment and follow-up.
   BJU Int. 2025;136:2-3.
   PubMed        
   
   
3. EID N, Lepor H
   Incidence, surveillance and natural history of high-grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy.
   BJU Int. 2025;136:159-164.
   PubMed         Abstract available
   
   
4. ROBERTS MJ, Arora S, Yao HH, Hogan D, et al
   Transperineal prostate biopsy under local vs general anaesthesia: a cost-effectiveness analysis.
   BJU Int. 2025;136:128-134.
   PubMed         Abstract available
   
   
5. HAGMAN A, Lantz A, Grannas D, Carlsson S, et al
   Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups.
   BJU Int. 2025;136:135-142.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. AHMADIANPOUR MV, Aleyasin SA
   CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis.
   BMC Urol. 2025;25:145.
   PubMed         Abstract available
   
   

   
   Br J Radiol

7. MARGOLESE N, Dahan J, Olivie DAR, Billiard JS, et al
   Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy.
   Br J Radiol. 2025 Jun 2:tqaf122. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. JOSEFSSON A, Carlsson SV, Lilja H, Godtman R, et al
   Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in th
   Eur Urol. 2025;87:e112-e113.
   PubMed        
   
   
9. DE BONO JS, He M, Shi Z, Nowicka M, et al
   Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.
   Eur Urol. 2025;87:672-682.
   PubMed         Abstract available
   
   
10. AL-MONAJJED R, Boschheidgen M, Lakes J, Krilaviciute A, et al
    Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
    Eur Urol. 2025 Jun 2:S0302-2838(25)00298-2. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. PATTOU M, Neuzillet Y, Ghoneim T, Bosset PO, et al
    Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching.
    Int J Urol. 2025 Jun 4. doi: 10.1111/iju.70142.
    PubMed         Abstract available
    
    
12. MA J, Qu X
    VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m(6)A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species.
    Int J Urol. 2025 Jun 3. doi: 10.1111/iju.70140.
    PubMed         Abstract available
    
    

    
    J Clin Lab Anal

13. SERKAN Y, Caner E, Serkan A, Bulent K, et al
    Significance of Inflammation Markers to Predict Curative Treatment for Prostate Cancer Patients on Active Surveillance.
    J Clin Lab Anal. 2025 May 31:e70059. doi: 10.1002/jcla.70059.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

14. STEIN MN, Vinceneux A, Robbrecht D, Doger B, et al
    Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study.
    J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678.
    PubMed         Abstract available
    
    

    
    J Natl Med Assoc

15. LEADER AE, Godbolt JB, Crumpler N, Gross L, et al
    Utilizing peer educators to increase genetic testing for prostate cancer among black males: results of a randomized controlled trial.
    J Natl Med Assoc. 2025 May 29:S0027-9684(25)00040.
    PubMed         Abstract available
    
    

    
    J Nucl Med

16. SCHMITL S, Kretschmer-Chott E, Patronas EM, Kramer G, et al
    Efficacy, Safety, Blood Kinetics, and (213)Bi Distribution Studies of [(225)Ac]Ac-SibuDAB in Prostate Cancer Patients.
    J Nucl Med. 2025 Jun 5:jnumed.125.269655. doi: 10.2967/jnumed.125.269655.
    PubMed         Abstract available
    
    
17. FANTI S, Robles Barba JJ, Behr S, Maurer T, et al
    Imaging Efficacy of [(18)F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269266. doi: 10.2967/jnumed.124.269266.
    PubMed         Abstract available
    
    
18. GAFITA A, Schroeder JA, Ceci F, Oldan JD, et al
    Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
    J Nucl Med. 2025 Jun 5:jnumed.124.268071. doi: 10.2967/jnumed.124.268071.
    PubMed         Abstract available
    
    
19. MURTHY V, Ludwig V, Gafita A, Hope TA, et al
    The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Feb 27:jnumed.124.268818. doi: 10.2967/jnumed.124.268818.
    PubMed         Abstract available
    
    

    
    J Urol

20. WAGGENER K, Snipes M, Rais-Bahrami S
    Editorial Comment on: "Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value".
    J Urol. 2025 Jun 4:101097JU0000000000004620. doi: 10.1097/JU.0000000000004620.
    PubMed        
    
    
21. LEWICKI P, Borza T
    Editorial Comment: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value.
    J Urol. 2025 Jun 4:101097JU0000000000004621. doi: 10.1097/JU.0000000000004621.
    PubMed        
    
    

    
    Magn Reson Imaging

22. WANG YF, Tadimalla S, Thiruthaneeswaran N, Holloway L, et al
    Longitudinal quantitative MRI in prostate cancer after radiation therapy with and without androgen deprivation therapy.
    Magn Reson Imaging. 2025;122:110431.
    PubMed         Abstract available
    
    
23. ZHANG P, Feng Z, Chen S, Zhu J, et al
    Accelerating prostate rs-EPI DWI with deep learning: Halving scan time, enhancing image quality, and validating in vivo.
    Magn Reson Imaging. 2025;121:110418.
    PubMed         Abstract available
    
    

    
    PLoS Biol

24. KAWAMURA T, Shigematsu M, Kirino Y
    A hormone-dependent tRNA half promotes cell cycle progression via destabilization of p21 mRNA.
    PLoS Biol. 2025;23:e3003194.
    PubMed         Abstract available
    
    

    
    PLoS One

25. 
    Retraction: Evidence for a Pro-proliferative Feedback Loop in Prostate Cancer: The role of Epac1 and COX-2-dependent Pathways.
    PLoS One. 2025;20:e0325680.
    PubMed        
    
    
26. 
    Retraction: Receptor-Recognized alpha2-Macroglobulin Binds to Cell Surface-Associated GRP78 and Activates mTORC1 and mTORC2 Signaling in Prostate Cancer Cells.
    PLoS One. 2025;20:e0325675.
    PubMed        
    
    
27. ROTTEVEEL A, Lee WY, Kountouri Z, Stefanou N, et al
    Towards robust medical machine olfaction: Debiasing GC-MS data enhances prostate cancer diagnosis from urine volatiles.
    PLoS One. 2025;20:e0314742.
    PubMed         Abstract available
    
    
28. HOUSTEN AJ, Chang SH, Rice HE, L'Hotta AJ, et al
    Costs of non-metastatic prostate cancer treatment among privately insured men in the United States.
    PLoS One. 2025;20:e0324902.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

29. PAPPAS K, Ferrari M, Smith P, Nandakumar S, et al
    BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.
    Proc Natl Acad Sci U S A. 2025;122:e2426743122.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

30. RAJEEV R, Hussain HK
    The TRANSLATE Trial: Transrectal versus Transperineal Biopsy for Prostate Cancer Detection.
    Radiol Imaging Cancer. 2025;7:e259010.
    PubMed        
    
    
31. ZABIHOLLAHY F, Wu HH, Sisk AE, Reiter RE, et al
    Deep Learning-based Anatomy-Aware Morph Model for Registration of Prostate Whole-Mount Histopathology to MRI.
    Radiol Imaging Cancer. 2025;7:e240336.
    PubMed         Abstract available
    
    

    
    Urology

32. FRIEDRICH NA, Kokorowski P, Luu M, Chaplin A, et al
    Topic Mapping to Inform Content to Discuss in Shared Decision-Making for Prostate Cancer.
    Urology. 2025 May 28:S0090-4295(25)00511-4. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.